EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Structure-Guided Design of Calcium-Dependent Protein Kinase 1 Inhibitors for Cryptosporidiosis

Wissarut Wijitrmektong iD, Ryan Choi iD, Matthew A Hulverson iD, Lijun Liu iD, Anne Cooper iD, Kevin P Battaile iD, Elizabeth K Harmon iD, Denise Ann Dayao iD, Lauren Huerta, Saul Tzipori, Case W McNamara iD, Malina A Bakowski iD und 3 weitere

The Journal of Infectious Diseases · 2026

DOI: 10.1093/infdis/jiag242 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Infectious Diseases, 2026. Verfasst von Wissarut Wijitrmektong und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, Houston, Texas, USA. Hauptthemen laut MEDLINE: Protein Kinase Inhibitors, Cryptosporidiosis, Protein Kinases, Cryptosporidium. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, NIAID NIH HHS, Wellcome Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Calcium-dependent protein kinase 1 (CDPK1) has emerged as a protozoan-specific target for the treatment of cryptosporidiosis. A previous study identified pyridopyrimidinones as new Cryptosporidium parvum CDPK1 (CpCDPK1) inhibitors with potent growth inhibition against C. parvum and Cryptosporidium hominis. Docking analyses suggested the unique positioning of the kinase's αC-helix could present refinement opportunities.

Methods

Compounds designed to optimize the pyridopyrimidinones focused on the back-pocket region predicted to be proximal to the αC-helix, the solvent-exposed region, and the ATP ribose-binding site. Designed derivatives were synthesized and assessed for CpCDPK1 and Src kinase inhibition and for Cryptosporidium spp growth inhibition in mammalian cells. AMP/Mg+2 and 3 inhibitors were cocrystalized with CpCDPK1, and 2 inhibitors were profiled for kinase selectivity.

Results

WIN 4-88 was identified with CpCDPK1 (half maximum inhibitory concentration [IC50] = 0.056 μM), and growth inhibition of zoonotic C. parvum NLuc (half maximum effective concentration [EC50] = 0.042 μM), anthroponotic C. parvum Tu114 (EC50 = 0.030 μM), and C. hominis Tu502 (EC50 = 0.062 μM), as well as enhanced kinome selectivity. The crystal structures confirmed the predicted binding mode, indicating key interactions with hinge residue Y155, similar orientations of the solvent-expose moieties, occupancy of the back pocket near the αC-helix, and for 1 inhibitor containing a solubilizing hydroxyethyl attached to the central heterocycle extension into the ATP ribose-binding site.

Conclusions

The expanded structure-activity relationship and structural insights will potentially be applicable to other chemotypes with similar binding modes and will enhance development of CpCDPK1 inhibitors for the treatment of cryptosporidiosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein Kinase InhibitorsCryptosporidiosisProtein KinasesCryptosporidiumAntiprotozoal AgentsProtozoan ProteinsHumansCryptosporidium parvumDrug DesignAnimalsMolecular Docking SimulationStructure-Activity Relationship

Stichwörter der Autor:innen

CryptosporidiumCDPK1calcium-dependent protein kinase 1chemotypeinhibitorpyridopyrimidinone

Substanzen

Protein Kinase InhibitorsProtein KinasesAntiprotozoal AgentsProtozoan Proteins

Autor:innen und Institutionen

  • Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, Houston, Texas, USA.
  • Department of Allergy and Infectious Diseases, Center for Emerging and Re-emerging Infectious Disease, University of Washington, Seattle, Washington, USA.
  • Protein Structure and X-ray Crystallography Laboratory, Del Shankel Structural Biology Center, University of Kansas, Lawrence, Kansas, USA.
  • Seattle Structural Genomics Center for Infectious Diseases, Seattle Children's Research Institute, Seattle, Washington, USA.
  • X-ray Department, New York Structural Biology Center, New York, New York, USA.
  • Department of Infectious Disease and Global Health, Cummings School of Veterinary Medicine, Tufts University, North Grafton, Massachusetts, USA.

ORCID-Profile: Wissarut Wijitrmektong, Ryan Choi, Matthew A Hulverson, Lijun Liu, Anne Cooper, Kevin P Battaile, Elizabeth K Harmon, Denise Ann Dayao, Case W McNamara, Malina A Bakowski, Scott Lovell, Wesley C Van Voorhis, Gregory D Cuny

Förderung

  • NIH HHS
  • NIAID NIH HHS
  • Wellcome Trust
  • Department of Energy
  • National Institutes of Health

Zitieren

APA

Wijitrmektong, W., Choi, R., Hulverson, M. A., Liu, L., Cooper, A., Battaile, K. P., Harmon, E. K., Dayao, D. A., Huerta, L., Tzipori, S., McNamara, C. W., Bakowski, M. A., Lovell, S., Van Voorhis, W. C., & Cuny, G. D. (2026). Structure-Guided Design of Calcium-Dependent Protein Kinase 1 Inhibitors for Cryptosporidiosis. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiag242

Vancouver

Wijitrmektong W, Choi R, Hulverson MA, Liu L, Cooper A, Battaile KP, et al. Structure-Guided Design of Calcium-Dependent Protein Kinase 1 Inhibitors for Cryptosporidiosis. The Journal of Infectious Diseases. 2026. doi:10.1093/infdis/jiag242

BibTeX
@article{Wijitrmektong2026,
  author = {Wijitrmektong, Wissarut and Choi, Ryan and Hulverson, Matthew A and Liu, Lijun and Cooper, Anne and Battaile, Kevin P and Harmon, Elizabeth K and Dayao, Denise Ann and Huerta, Lauren and Tzipori, Saul and McNamara, Case W and Bakowski, Malina A and Lovell, Scott and Van Voorhis, Wesley C and Cuny, Gregory D},
  title = {Structure-Guided Design of Calcium-Dependent Protein Kinase 1 Inhibitors for Cryptosporidiosis},
  journal = {The Journal of Infectious Diseases},
  year = {2026},
  doi = {10.1093/infdis/jiag242}
}
Kostenlos starten →